Where patients reveal the biology.
QR Genetics is a human-first drug discovery and development company, turning real patient biology into new precision uses for existing drugs, accelerated by AI and validated in the clinic.
One path, walked many times.
Every program starts with a different rare genetic disease. Each one exposes a mechanism that also drives a far more common disease, so each program opens a different large population. The platform is the path, not a single asset.
- 01A patient with a rare genetic disease
- 02The causal mechanism that disease exposes
- 03An existing medicine that fits that mechanism
- 04Clinical validation, starting with that patient
- 05The common disease driven by the same mechanism
Each of these diseases is a different mechanism, and each mechanism points at a different common disease. Platform figures as submitted to the FDA, June 2026. Clinical outcomes are described in the peer-reviewed record.
A therapeutics company, not a data provider.
QR Genetics is a human-first, AI-enabled therapeutic discovery and development company uncovering new precision uses for existing drugs.
We begin with patients whose genetics reveal the biological drivers of disease. By combining human genetics, mechanistic biology, patient-derived evidence and AI, we identify existing drugs capable of correcting those mechanisms, and advance the most promising opportunities toward clinical development.
Some of the most important therapeutic insights begin with an individual patient.
Rare genetic mutations can expose the mechanisms driving disease with unusual clarity. QR Genetics learns from these patients to understand what has gone wrong biologically, identifies an existing drug that may correct it, and translates that insight into precision therapeutics.
Rare disease is our point of biological clarity, not the limit of our opportunity. A mechanism proven in one patient can carry into far larger populations.
From patient to precision medicine.
The platform integrates human genetics, multidimensional biological data, mechanistic modelling and AI. Each step depends on the one before it.
Identify the genetic driver of disease
Discovery begins with real patients and the mutations that make their disease legible.
Decode how the mutation disrupts biological function
Mechanistic, mutation-specific modelling explains what has actually gone wrong.
Match the mechanism with an existing drug
Drug selection is based on biological fit, not correlation alone.
Validate the hypothesis in human-relevant models and patients
Predictions are tested where they matter most.
Develop new, protectable precision indications
A validated mechanism becomes a differentiated asset.
Expand validated insights into larger populations
The same mechanism is evaluated in related, more prevalent diseases.
AI helps us analyse and connect the evidence. Human biology determines where we begin, and clinical translation determines what moves forward.
We unlock new precision uses for medicines that already exist.
A known clinical history
We work with existing molecules whose behaviour in humans is already documented.
Less early risk, cost and time
Starting from an approved molecule removes much of the uncertainty that sinks early development.
Differentiated, protectable assets
A new mechanism-led indication can stand on its own intellectual property.
A pipeline built from human evidence.
Programs across cardiovascular, immunology, inflammation, autoimmune, renal and rare disease. Each begins with human genetic evidence and advances through mechanistic understanding and therapeutic matching.
Unlock new value from the molecules you already own.
We help pharmaceutical companies identify new, biologically grounded and potentially protectable indications for existing, shelved, deprioritised, failed or patent-maturing drugs.